Tumor targeting DVDMS-nanoliposomes for an enhanced sonodynamic therapy of gliomas

2019 ◽  
Vol 7 (3) ◽  
pp. 985-994 ◽  
Author(s):  
Yue Sun ◽  
Haiping Wang ◽  
Pan Wang ◽  
Kun Zhang ◽  
Xiaorui Geng ◽  
...  
Keyword(s):  
Tumor Targeting ◽  
Sonodynamic Therapy ◽  
Tumor Penetration ◽  
Specific Targeting ◽  
Targeting Ability

UTMD-assisted intelligent DVDMS encapsulate iRGD-Liposomes mediate SDT with deep tumor penetration and specific targeting ability enhanced anti-glioma efficacy.

iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment

2020 ◽  
Vol 20 ◽  
Author(s):  
Li Li ◽  
Mi Yang ◽  
Rutian Li ◽  
Jing Hu ◽  
Lixia Yu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Targeting ◽  
Antitumor Effect ◽  
Plga Nanoparticles ◽  
Specific Targeting ◽  
Cancer Models ◽  
Cell Experiment ◽  
Targeting Ability ◽  
Targeting Effect ◽  
Colorectal Cancer Treatment

Objective: To explore the targeting effect of PLGA-NP and iRGD co-administration with PTX-PLGA NP (PTX-PLGA + iRGD) on colorectal cancer. Methods: Whether PLGA-NP co-administration with iRGD peptide could show effective tumor-targeting ability in contrast to with PLGA-NP in colorectal cancer mice models was evaluated. Moreover, the chemotherapeutics paclitaxel (PTX) was loaded into the PLGA-NP to impart anti-tumor efficiency to the PTX-PLGA. Whether iRGD co-administration with PTX-PLGA NP (PTX-PLGA + iRGD) in colorectal cancer models enabled PTX to achieve better anti-tumor efficiency and biocompatibility was further assessed. Results: The targeting ability of PLGA-NP was enhanced in cell experiment and colorectal cancer mice models by coadministration of iRGD. As a result, PTX-PLGA + iRGD achieved better anti-tumor efficacy than PTX and PTX-PLGA. Conlusion: The nanocarrier based on PLGA with specific targeting ability could promote the clinical application of various chemotherapeutics similar to PTX. The combination of drug-loaded nanoparticles and iRGD could develop into a promising drug delivery system.

Fluorescence-guided magnetic nanocarriers for enhanced tumor targeting photodynamic therapy

2018 ◽  
Vol 6 (28) ◽  
pp. 4676-4686 ◽  
Author(s):  
Khalilalrahman Dehvari ◽  
Po-Ting Lin ◽  
Jia-Yaw Chang
Keyword(s):  
Photodynamic Therapy ◽  
Cancer Cells ◽  
Tumor Targeting ◽  
Therapeutic Effects ◽  
Specific Targeting ◽  
Nir Imaging ◽  
Targeting Ability ◽  
Magnetic Nanocarriers ◽  
Subsequent Improvement

Fe3O4-HA-Ce6 nanotheranostic agents demonstrated specific targeting ability toward cancer cells with subsequent improvement in dual modal MR/NIR imaging and photodynamic therapeutic effects.

scholarly journals Patient-Derived Microvesicles/AIE Luminogen Hybrid System for Personalized Sonodynamic Cancer Therapy in Patient-Derived Xenograft Models

2020 ◽  
Author(s):  
Daoming Zhu ◽  
Zheng Zheng ◽  
Meng Suo ◽  
zeming liu ◽  
Yanhong Duo ◽  
...  
Keyword(s):  
Hybrid System ◽  
Bladder Cancer Patient ◽  
Tumor Treatment ◽  
Sonodynamic Therapy ◽  
Tumor Penetration ◽  
Patient Derived Xenograft ◽  
New Ideas ◽  
Xenograft Models ◽  
Targeting Ability ◽  
Pdx Models

<p>Sonodynamic therapy (SDT), as an efficient way of tumor treatment, has the advantages of deep tumor penetration and high therapeutic efficacy. However, developing efficient sonosensitizers are still challenging. AIEgen-based SDT has never been reported and it is urgent to develop novel AIEgen-active sonosensitizers. Furthermore, the AIEgen-based theranostic system is promisingly needed to be proved on PDX models to be closer to the clinic. Herein, we constructed the first AIEgen based SDT system and found that DCPy has advantages over traditional sonosensitizers in SDT. Then, a patient-derived MVs/AIEgen hybrid system prepared by electroporation was used for personalized SDT in bladder cancer patient-derived xenograft (PDX) models. Impressively, AMVs displayed the superior tumor targeting ability and efficient personalized SDT therapy on PDX models, both of which were much more improved compared with PLGA/AIEgens nanoparticles and cell line-derived micro vesicles. This work presented the first example of an AIEgen-based hybrid system as <a></a><a>sonosensitizer</a> for SDT and provides new ideas for both the design of AIE-active sonosensitizers and the SDT treatment of cancers, further expanding the potential clinical application of AIEgens in the future.</p>

scholarly journals Patient-Derived Microvesicles/AIE Luminogen Hybrid System for Personalized Sonodynamic Cancer Therapy in Patient-Derived Xenograft Models

2020 ◽  
Author(s):  
Daoming Zhu ◽  
Zheng Zheng ◽  
Meng Suo ◽  
zeming liu ◽  
Yanhong Duo ◽  
...  
Keyword(s):  
Hybrid System ◽  
Bladder Cancer Patient ◽  
Tumor Treatment ◽  
Sonodynamic Therapy ◽  
Tumor Penetration ◽  
Patient Derived Xenograft ◽  
New Ideas ◽  
Xenograft Models ◽  
Targeting Ability ◽  
Pdx Models

<p>Sonodynamic therapy (SDT), as an efficient way of tumor treatment, has the advantages of deep tumor penetration and high therapeutic efficacy. However, developing efficient sonosensitizers are still challenging. AIEgen-based SDT has never been reported and it is urgent to develop novel AIEgen-active sonosensitizers. Furthermore, the AIEgen-based theranostic system is promisingly needed to be proved on PDX models to be closer to the clinic. Herein, we constructed the first AIEgen based SDT system and found that DCPy has advantages over traditional sonosensitizers in SDT. Then, a patient-derived MVs/AIEgen hybrid system prepared by electroporation was used for personalized SDT in bladder cancer patient-derived xenograft (PDX) models. Impressively, AMVs displayed the superior tumor targeting ability and efficient personalized SDT therapy on PDX models, both of which were much more improved compared with PLGA/AIEgens nanoparticles and cell line-derived micro vesicles. This work presented the first example of an AIEgen-based hybrid system as <a></a><a>sonosensitizer</a> for SDT and provides new ideas for both the design of AIE-active sonosensitizers and the SDT treatment of cancers, further expanding the potential clinical application of AIEgens in the future.</p>

scholarly journals AIE nanoparticles camouflaged with tumor cell-derived exosomes for NIR-II imaging-guided photothermal therapy

2021 ◽  
Author(s):  
Yirun Li ◽  
Xiaoxiao Fan ◽  
Yuanyuan Li ◽  
Runze Chen ◽  
Huwei Ni ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Photothermal Therapy ◽  
Tumor Targeting ◽  
Near Infrared ◽  
Specific Targeting ◽  
Specific Tumor ◽  
Targeting Ability ◽  
Targeting Strategy

Nanoparticles (NPs) assisted photothermal therapy (PTT) is a promising cancer treatment modality and has attracted the attention of the scientific mainstream. However, developing NPs that exhibit efficient optical properties and specific tumor targeting capability simultaneously is difficult. Herein, we develop hybrid nanovesicles consisting of tumor cell-derived exosomes (EXO) and organic aggregation-induced emission (AIE) nanoparticles (TT3-oCB NP@EXOs) with enhanced second near-infrared (NIR-II, 900-1700 nm) fluorescence property and PTT functionality. Compared with TT3-oCB NPs, TT3-oCB NP@EXOs exhibit excellent biocompatibility, specific targeting ability in vitro, homing to homologous tumors in vivo, and prolonged circulation time. Furthermore, TT3-oCB NP@EXOs were utilized as biomimetic NPs for NIR-II fluorescence imaging-guided PTT of tumors, due to their high and stable photothermal conversion capacity under 808 nm irradiation. Therefore, the tumor cell-derived EXO/AIE NP hybrid nanovesicles may provide an alternative artificial targeting strategy for improving tumor diagnosis and PTT.

scholarly journals A Novel TMTP1-modified Theranostic Nanoplatform for Targeted in Vivo NIR-II Fluorescence Imaging-guided Chemotherapy of Cervical Cancer

2021 ◽  
Author(s):  
Alifu Nuernisha ◽  
Rong Ma ◽  
Lijun Zhu ◽  
Zhong Du ◽  
Shuang Chen ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Blood Vessels ◽  
Fluorescence Imaging ◽  
Spatial Resolution ◽  
Self Assembly ◽  
Tumor Targeting ◽  
High Sensitivity ◽  
High Definition ◽  
Targeting Ability

Abstract BackgroundNear-infrared II (NIR-II, 900-1700 nm) fluorescence bioimaging with advantages of good biosafety, excellent spatial resolution, high sensitivity and contrast, has attracted great attentions in biomedical research fields. However, most nanoprobes used for NIR-II fluorescence imaging have poor tumor-targeting ability and therapeutic efficiency. To overcome these limitations, a novel NIR-II-emissive theranostic nanoplatform for imaging and treatment of cervical cancer was designed and prepared. The NIR-II-emissive dye IR-783 and chemotherapy drug doxorubicin (DOX) were encapsulated into liposomes, and the tumor-targeting peptide TMTP1 was conjugated to the surface of the liposomes to form IR-783-DOX-TMTP1 nanoparticles (NPs) via self-assembly methods.ResultsThe IR-783-DOX-TMTP1 NPs showed strong NIR-II emission, excellent biocompatibility, a long lifetime, and low toxicity. Further, high-definition NIR-II fluorescence microscopy images of ear blood vessels and intratumor blood vessels were obtained from IR-783-DOX-TMTP1 NPs-stained mice with high spatial resolution under 808 nm laser excitation. Moreover, IR-783-DOX-TMTP1 NPs showed strong tumor targeting ability and high efficiently chemotherapeutic character towards cervical tumors. ConclusionsThe novel targeting and NIR-II-emissive IR-783-DOX-TMTP1 NPs have potential in diagnosis and therapy for cervical cancer.

In vitro evaluation of tumor targeting ability of a parenteral enoxaparin-coated self-emulsifying drug delivery system

2019 ◽  
Vol 53 ◽  
pp. 101144 ◽  
Author(s):  
Simona Giarra ◽  
Noemi Lupo ◽  
Virginia Campani ◽  
Alfonso Carotenuto ◽  
Laura Mayol ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Tumor Targeting ◽  
In Vitro Evaluation ◽  
Targeting Ability

GRPR-targeted SPECT imaging using a novel bombesin-based peptide for colorectal cancer detection

2020 ◽  
Vol 8 (23) ◽  
pp. 6764-6772 ◽  
Author(s):  
Peifei Liu ◽  
Yuanbiao Tu ◽  
Ji Tao ◽  
Zicun Liu ◽  
Fang Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Detection ◽  
Tumor Targeting ◽  
Spect Imaging ◽  
Intestinal Activity ◽  
Cancer Models ◽  
Pharmacokinetic Properties ◽  
Targeting Peptide ◽  
Targeting Ability

The designed novel targeting peptide GB-6 binding to GRPR possesses more favorable pharmacokinetic properties with lower intestinal activity as well as superior tumor-targeting ability in colorectal cancer models than BBN7–14.

Construction of a pH/TGase “Dual Key”-Responsive Gold Nano-radiosensitizer with Liver Tumor-Targeting Ability

2021 ◽  
Author(s):  
Zhenjie Zhang ◽  
Xiaoyan Niu ◽  
Xiaoyue Feng ◽  
Xiaohui Wang ◽  
Licheng Yu ◽  
...  
Keyword(s):  
Liver Tumor ◽  
Tumor Targeting ◽  
Targeting Ability

scholarly journals Systemic siRNA delivery to tumors by cell-penetrating α-helical polypeptide-based metastable nanoparticles

Nanoscale ◽  
2018 ◽  
Vol 10 (32) ◽  
pp. 15339-15349 ◽  
Author(s):  
Yang Liu ◽  
Ziyuan Song ◽  
Nan Zheng ◽  
Kenya Nagasaka ◽  
Lichen Yin ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Tumor Targeting ◽  
Sirna Delivery ◽  
Tumor Penetration ◽  
Cell Internalization ◽  
Cell Penetrating

Metastable nanoparticles capable of tumor targeting, tumor penetration, and selective tumor cell internalization were developed based on membrane penetrating, helical polypeptide PVBLG-8 and anionic PLG, for the efficient encapsulation and delivery of EGFR siRNA.

Sign in / Sign up

Export Citation Format

Share Document